Open AccessReal‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
Author(s) -
Mian Hira,
LeBlanc Richard,
Louzada Martha,
MasihKhan Esther,
McCurdy Arleigh,
Venner Christopher P.,
Stakiw Julie,
Kardjadj Moustafa,
JimenezZepeda Victor H.,
Sebag Michael,
White Darrell,
Aslam Muhammad,
Song Kevin,
Reiman Anthony,
Kotb Rami,
Gul Engin,
Reece Donna
Publication year - 2023
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.5245
Subject(s) - lenalidomide , multiple myeloma , medicine , dosing , dexamethasone , oncology
Using the Canadian Myeloma Research Group Database, a retrospective study of 167 newly diagnosed, transplant‐ineligible patients with multiple myeloma (MM) that received lenalidomide‐dexamethasone as front‐line treatment was conducted to understand the impact of lenalidomide dosing. Starting dose modifications were common, 42% of patients started on lenalidomide <25 mg with normal renal function. During treatment course, 35% of patients required further dose reduction. Dose reductions in the first year did not have an impact on progression free survival or overall survival. Further studies need to be conducted to understand the impact of dosing strategies of anti‐MM agents in the real world.